Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Novartis Allays Concerns Over Cosentyx Sales Miss

The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.

Sales & Earnings Dermatology Immune Disorders

Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off

The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater flexibility in business development activities, but reducing net debt has first claim on the funds.

 

M & A Business Strategies Commercial

Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows

A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing. 

Pricing Strategies Pricing Debate Reimbursement
Advertisement


 Recent Tweets from Scrip


 

Commercial Explore this Topic

Set Alert for Commercial

Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid

Takeda's most recent offer for Shire had an estimated total value of $61bn, but likely included too much equity and too little cash. The companies continue negotiating as an April 25 deadline looms, while Allergan stated it won't bid for Shire.
M & A Business Strategies Commercial

US Generic Drug Spending Declines In A New Development – IQVIA Report

Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.

Generic Drugs Biosimilars Market Intelligence

Novo Seeds: Investing In Biopharma Growth

Stephan Christgau, a senior partner at Novo Seeds, talks about the firm’s approach to early-stage funding in biotech and how this financing arm aligns with Novo’s broader strategy.

StartUps and SMEs Commercial

TVM Raises White Flag On Biovertis & Morphochem

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.

Commercial M & A

Struggling Fibrocell To Consider All Strategic Directions Going Forward

Focused on autologous fibroblast cell therapies for rare diseases, the biotech appears cash-poor despite one candidate moving into Phase II and another ready to enter the clinic.
Business Strategies Commercial

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

Market Intelligence Infectious Diseases

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.

Business Strategies Companies

AstraZeneca Bolstering India Play With $90m Investment Plan

AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.

Commercial Strategy

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

China Vs Cancer: An Infographic Snapshot

Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs  from May.

Cancer China Policy & Regulation

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.

Business Strategies Companies

India Leads Global 65% Surge In Antibiotics Use

Human antibiotic consumption globally jumped dramatically between 2000 and 2015, with India posting the biggest rise, reports a new US study, which calls for a radical policy rethink to prevent antimicrobial drug resistance soaring.

India Policy & Regulation

FDA Reversal Puts Alkermes Depression Drug Back On Track For January Approval

Reversing an earlier decision, FDA accepted Alkermes' new drug application (NDA) for ALKS 5461 for review, with a target action date of Jan. 31. But the company could still face a tough FDA review.

Drug Review Neurology

Research & Development Explore this Topic

Set Alert for Research & Development

Experts Challenge GSK Triple Inhaled COPD Therapy Claims

While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.

Clinical Trials Research & Development Respiratory

Publisher's Spotlight: The 2018 Scrip Awards Is Now Open For Entries

Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for entries.

Companies Research & Development

BenevolentAI Scoops $115M For AI Drug Development

At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.

Artificial Intelligence Financing

With Back-To-Back FDA Holds, Solid Hopes To Regain Footing For Duchenne Candidate

The US FDA wants more information on the first patient given SGT-001, who was hospitalized with a reduced platelet count after dosing. Solid says the patient is doing well and hopes to reply to the FDA's concerns within weeks.
Research & Development Clinical Trials
UsernamePublicRestriction

Register

Advertisement